An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease.
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Siltuximab (Primary)
- Indications Giant lymph node hyperplasia
- Focus Adverse reactions
- Sponsors Janssen Research & Development; Janssen-Cilag
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.
- 24 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Feb 2018.
- 14 May 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History